[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649576":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":24,"centralContacts":28,"locations":34,"responsibleParty":62,"collaborators":64,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":69,"sex":74,"minAge":75,"maxAge":10,"enrollmentInfo":76,"targetDuration":10,"studyType":79,"phases":10,"briefSummary":80,"conditions":81,"keywords":83,"overallStatus":94,"whyStopped":10,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"University Hospital, Montpellier","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"patients with ALS",null,"ALS patients under follow-up",[13,14],"Other: peripheral venous blood collection","Other: collection of medical data related to patient care",[16,20],{"type":6,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"peripheral venous blood collection","collection of an additional 24 mL of blood following a routine blood draw",[9],{"type":6,"name":21,"description":22,"armGroupLabels":23,"otherNames":10},"collection of medical data related to patient care","collection of medical data from patient care during the 12-month follow-up period, drawn from electronic medical records, including laboratory test results, clinical examination findings, and paraclinical test results",[9],[25],{"name":26,"affiliation":5,"role":27},"Florence ESSELIN, MD","PRINCIPAL_INVESTIGATOR",[29],{"name":26,"role":30,"phone":31,"phoneExt":32,"email":33},"CONTACT","04 67 33 09 56","+33","motoneuronerech@chu-montpellier.fr",[35,48],{"facility":36,"status":10,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":10},"Montpellier University Hospital","Montpellier","Occitanie","34295","France","FR",{"type":43,"coordinates":44},"Point",[45,46],3.87635,43.61093,{"lat":46,"lon":45},{"facility":49,"status":10,"city":50,"state":10,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":58,"contacts":59},"Hospital Universitari Vall D'Hebron","Barcelona","08035","Spain","ES",{"type":43,"coordinates":55},[56,57],2.15899,41.38879,{"lat":57,"lon":56},[60],{"name":61,"role":30,"phone":10,"phoneExt":10,"email":10},"Raúl Juntas Morales, MD PhD",{"type":63,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[65],{"name":66,"class":6},"Hospital Universitari Vall d'Hebron Research Institute","100649576","developing-a-comprehensive-biomarker-panel-for-monitoring-progression-and-early-detection-in-als-patients-100649576",false,"NCT07737977","Developing a Comprehensive Biomarker Panel for Monitoring Progression and Early Detection in ALS Patients","UNZUELUZON ALS","Inclusion Criteria:\n\n* Age greater than 18 years.\n* Male and female patients with ALS diagnosed according to the El Escorial diagnostic criteria.\n* Sporadic or familial ALS cases.\n* Spinal-onset or bulbar-onset ALS cases.\n\nExclusion Criteria:\n\n* Refusal to participate.\n* Individuals deprived of liberty (Article L1121-6), including those subject to judicial or administrative decisions or involuntary hospitalization.\n* Adults under legal protection (guardianship, curatorship, or judicial protection measures) (Article L1121-8).\n* Individuals not affiliated with, or not beneficiaries of, a French social security scheme (Article L1121-8-1).\n* Individuals participating in another research study with an ongoing exclusion period (Article L1121-12).","ALL","18 Years",{"count":77,"type":78},200,"ESTIMATED","OBSERVATIONAL","Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which reliable biomarkers for early diagnosis, prognosis, and patient stratification remain limited. Previous genetic, proteomic, imaging, and electrophysiological studies have identified potential biomarkers and phenotype modifiers, improving the understanding of motor neuron degeneration mechanisms. However, these findings have not yet been translated into a clinically useful biomarker algorithm. This observational study aims to develop a biomarker panel to support the diagnosis, prognosis, and stratification of patients with ALS. Clinical and molecular biomarkers previously associated with ALS phenotypes will be analyzed simultaneously and integrated into a multivariable predictive model. Clinical data and biological samples will be collected and analyzed to identify combinations of biomarkers associated with ALS phenotypes.",[82],"ALS (Amyotrophic Lateral Sclerosis)",[84,85,86,87,88,89,90,91,92,93],"ALS","Biomarkers","Amyotrophic Lateral Sclerosis","Diagnosis","Prognosis","Disease Progression","Patient Stratification","Blood Biomarkers","Motor Neuron Disease","Neurodegeneration","NOT_YET_RECRUITING","2026-07-27",{"date":97,"type":98},"2026-07-30","ACTUAL",{"date":100,"type":78},"2026-08",{"date":102,"type":78},"2029-08",{"name":5,"class":6},2]